Key Takeaways
- Morgan Stanley elevated ARWR to Overweight from Equal-weight, setting a $100 price target versus prior $78
- Plozasiran Phase 3 results in severe hypertriglyceridemia anticipated Q3 2026
- Bank of America increased its price target, projecting approximately $3 billion peak market opportunity
- Morgan Stanley analyst now forecasts $3.2 billion peak sales for plozasiran, versus previous $1.7 billion estimate
- ARWR has gained 8.2% in 2025 and climbed 481% over the trailing twelve months
Arrowhead Pharmaceuticals (ARWR) delivered extraordinary returns over the past year, soaring 481%. The biotech stock extended its rally Tuesday with a 3.9% gain to $71.92, driven by Morgan Stanley’s upgrade and elevated price outlook to $100.
Arrowhead Pharmaceuticals, Inc., ARWR
Morgan Stanley’s new $100 price objective suggests potential upside of 39% from Tuesday’s close. Analyst Michael Ulz upgraded the shares to Overweight from Equal-weight, pointing to forthcoming Phase 3 trial data that he believes will “unlock a multibillion-dollar opportunity that remains underappreciated.”
The focus centers on plozasiran, Arrowhead’s primary investigational therapy targeting patients with severe hypertriglyceridemia (SHTG) — a metabolic disorder characterized by dangerously elevated triglyceride levels that increase cardiovascular disease and acute pancreatitis risk.
Phase 3 topline data is scheduled for Q3 2026. Drawing on earlier clinical findings and studies involving similar patient demographics, Ulz anticipates favorable outcomes. A successful data release could represent an inflection point for the organization.
Morgan Stanley joined other Wall Street firms in lifting expectations. BofA similarly increased its price objective, projecting a peak addressable market approaching $3 billion for plozasiran in SHTG — indicating growing analyst conviction around the drug’s revenue potential.
Ulz substantially revised his peak sales projection from $1.7 billion to $3.2 billion. The near-doubling reflects heightened confidence in market penetration, especially within high-risk pancreatitis cohorts.
Rival Threat From Ionis
Arrowhead faces competitive pressure in the SHTG landscape. Ionis Pharmaceuticals (IONS) is advancing olezarsen for the same indication. Ulz noted that Ionis “has set the price” as the market reference point.
Olezarsen currently carries approval exclusively for familial chylomicronemia syndrome, though it secured Breakthrough Therapy designation. A supplemental regulatory submission is under expedited FDA review with an action date of June 30.
Despite rivalry, Ulz maintains there’s sufficient market space for multiple therapies. He views plozasiran as possessing robust standalone commercial viability, particularly among pancreatitis patients.
Regulatory Milestones and Development History
Arrowhead filed its inaugural New Drug Application for plozasiran in late 2024. This submission represented a strategic evolution — transforming the enterprise from research-oriented biotech toward commercial-stage pharmaceutical company.
The organization has extensive RNA interference heritage. It acquired Roche’s RNAi operations in 2011, subsequently obtaining RNAi assets from Novartis in 2015. Johnson & Johnson’s Janssen division maintained partnership status until 2023, when Janssen restructured its infectious disease and vaccine initiatives.
Among the 12 analyst firms monitored by FactSet providing ARWR coverage, 10 maintain Buy-equivalent ratings. Only two firms — Leerink Partners and Bernstein Research — assign Hold ratings.
ARWR has advanced 8.2% year-to-date in 2025. Ionis, conversely, declined 6.2% in 2026 while posting 156% gains over the preceding 12 months.
The company’s market capitalization currently stands at $9.94 billion.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
